SCHEMBL22358235

SCHEMBL22358235

Cc1nn(C)c2cc(-c3noc(N4CCN(C(=O)[C@H]5CC(=O)N(c6ccccc6)C5)CC4)n3)cnc12

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ TSHR P16473 1/20 0.52
▸ MAPT P10636 8/20 0.46
▸ MAPK1 P28482 3/20 0.46
▸ PKM P14618 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ TP53 P04637 4/20 0.45
▸ POLB P06746 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ LMNA P02545 4/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ GLA P06280 1/20 0.41
▸ RAB9A P51151 1/20 0.40
▸ HTT P42858 2/20 0.40
▸ THRB P10828 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GRM5 P41594 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30506348 0.89 SMN1; SMN2 (0.51) SMN1; SMN2TSHRMAPTMAPK1PKM
SCHEMBL20116131 0.89 SMN1; SMN2 (0.51) SMN1; SMN2TSHRMAPTMAPK1PKM
SCHEMBL30506351 0.88 GRM5 (0.47) SMN1; SMN2TSHRNPC1GRM5
SCHEMBL20116503 0.88 GRM5 (0.47) SMN1; SMN2TSHRNPC1GRM5
SCHEMBL22358109 0.79 GRM5 (0.41) SMN1; SMN2MAPTLMNAHTTGRM5
SCHEMBL22358339 0.77 SMN1; SMN2 (0.51) SMN1; SMN2TSHRMAPTMAPK1PKM
SCHEMBL20116106 0.77 GRM5 (0.47) SMN1; SMN2TSHRNPC1GRM5
SCHEMBL30506344 0.77 GRM5 (0.47) SMN1; SMN2TSHRNPC1GRM5
SCHEMBL20116104 0.77 GRM5 (0.47) SMN1; SMN2TSHRNPC1GRM5
SCHEMBL20116103 0.77 GRM5 (0.47) SMN1; SMN2TSHRNPC1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 SMN1; SMN2 13/4885TSHR 4679/4885MAPT 22/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 SMN1; SMN2 13/4885TSHR 4679/4885MAPT 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback